Literature DB >> 25246463

Nabilone therapy for cannabis withdrawal presenting as protracted nausea and vomiting.

Philip W Lam1, David W Frost2.   

Abstract

Cannabis is one of the most commonly used recreational drugs worldwide. Psychoactive properties of the principal compound, δ-9-tetrahydrocannabinol include euphoria, a sense of relaxation and increased appetite. Chronic cannabis use has been associated with the development of a withdrawal syndrome on abrupt discontinuation. Withdrawal symptoms typically begin within 24 h of abstinence and manifest as irritability, nervousness, sleep disturbances and decreased appetite. There is growing evidence that supports the use of plant-derived and synthetic cannabinoids for the treatment of cannabis withdrawal. In this case report, we present 20-year-old woman who developed protracted nausea and vomiting secondary to cannabis withdrawal and was successfully treated with nabilone. Nausea and vomiting is not listed in the Diagnostic and Statistical Manual-5 diagnostic criteria for cannabis withdrawal syndrome and is an uncommon symptom presentation. 2014 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25246463      PMCID: PMC4173142          DOI: 10.1136/bcr-2014-205287

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.

Authors:  Gillinder Bedi; Ziva D Cooper; Margaret Haney
Journal:  Addict Biol       Date:  2012-01-19       Impact factor: 4.280

2.  Marijuana withdrawal among adults seeking treatment for marijuana dependence.

Authors:  A J Budney; P L Novy; J R Hughes
Journal:  Addiction       Date:  1999-09       Impact factor: 6.526

3.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

4.  Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms.

Authors:  Alan J Budney; Ryan G Vandrey; John R Hughes; Brent A Moore; Betsy Bahrenburg
Journal:  Drug Alcohol Depend       Date:  2006-06-12       Impact factor: 4.492

5.  Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.

Authors:  Kenneth H Levin; Marc L Copersino; Stephen J Heishman; Fang Liu; Deanna L Kelly; Douglas L Boggs; David A Gorelick
Journal:  Drug Alcohol Depend       Date:  2010-05-26       Impact factor: 4.492

6.  Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating.

Authors:  Tyler Chesney; Laura Matsos; Jennifer Couturier; Natasha Johnson
Journal:  Int J Eat Disord       Date:  2013-11-26       Impact factor: 4.861

7.  Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Authors:  Margaret Haney; Ziva D Cooper; Gillinder Bedi; Suzanne K Vosburg; Sandra D Comer; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2013-02-26       Impact factor: 7.853

8.  Marijuana withdrawal in humans: effects of oral THC or divalproex.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Jennifer Nasser; Andrew Bennett; Carlos Zubaran; Richard W Foltin
Journal:  Neuropsychopharmacology       Date:  2004-01       Impact factor: 7.853

9.  Pharmacological treatment of cannabis dependence.

Authors:  A M Weinstein; David A Gorelick
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

10.  Time-course of the DSM-5 cannabis withdrawal symptoms in poly-substance abusers.

Authors:  Morten Hesse; Birgitte Thylstrup
Journal:  BMC Psychiatry       Date:  2013-10-12       Impact factor: 3.630

View more
  4 in total

1.  Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.

Authors:  Matisyahu Shulman; Mei-Chen Hu; Maria A Sullivan; Sarah C Akerman; James Fratantonio; Vincent Barbieri; Edward V Nunes; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2022-02-02       Impact factor: 4.492

Review 2.  The cannabis withdrawal syndrome: current insights.

Authors:  Udo Bonnet; Ulrich W Preuss
Journal:  Subst Abuse Rehabil       Date:  2017-04-27

3.  Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?

Authors:  Benedikt Bernd Claus; Michael Specka; Heath McAnally; Norbert Scherbaum; Fabrizio Schifano; Udo Bonnet
Journal:  Front Psychiatry       Date:  2020-12-03       Impact factor: 4.157

Review 4.  Marijuana for Glaucoma: A Recipe for Disaster or Treatment?

Authors:  Xiaoshen Sun; Chaoying S Xu; Nisha Chadha; Allshine Chen; Ji Liu
Journal:  Yale J Biol Med       Date:  2015-09-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.